Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model

Exclusion Criteria

• •Patients with gastrointestinal reflux disease.
• •Eosinophilic disease in the stomach or duodenum.
• •Peripheral eosinophil counts \>1500 (hyper eosinophilic syndrome).
• •Women of childbearing potential not using two forms of contraception method(s) including but not limited to condoms, diaphragm, oral contraceptive pills, other hormonal methods, intrauterine device or tubal ligation and vasectomy, as well as women who are breastfeeding
• •Known sensitivity to study drug(s) or class of study drug(s).
• •Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study (specify as required).
• •Use of any other investigational agent in the last 30 days.
• •Use of systemic or inhaled steroids within the past 1 month.
• •History of malignancy.
• •Require chronic immunosuppressive therapy including cyclosporine, methotrexate, etc.
• •Have been treated with Xolair within the 12 months prior to screening.
• •Patients with eosinophilic esophagitis in remission on swallowed steroids.
• •Patients with asthma taking inhaled steroids.
• •Serum IgE levels \< 30 IU/l or \> 700 IU/l